Cat. No. | Product name | CAS No. |
DC28073 |
CNX-500
Featured
CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC50 of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn. |
1202758-21-1 |
DC31047 |
ABBV-105
ABBV-105 (ABBV105) is a potent, selective, irreversible, covalent inhibitor of BTK with IC50 of 0.18 uM. |
|
DC31049 |
CB-988
CB-988 is a potent, highly selective, non-covalent Btk inhibitor targering ibrutinib-resistant Btk C481S mutant (IC50=0.6 nM). |
|
DC31063 |
PCI-32765 racemate
A potent a+M7692nd highly selective Btk inhibitor with IC50 of 0.5 nM. |
936563-87-0 |
DC39103 |
Remibrutinib (LOU064)
Featured
Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases. |
1787294-07-8 |
DC40447 |
N-piperidine Ibrutinib hydrochloride
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. |
2231747-18-3 |
DC41102 |
Acalabrutinib D4
Acalabrutinib D4 (ACP-196 D4) is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. |
|
DC41149 |
Ibrutinib deacryloylpiperidine
Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. |
330786-24-8 |
DC42420 |
Tolebrutinib
Featured
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant of Bruton tyrosine kinase (BTK), with IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib can be used for the research of multiple sclerosis (MS). |
1971920-73-6 |
DC42421 |
IBT6A
IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM. |
1022150-12-4 |
DC42422 |
IBT6A hydrochloride
IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM. |
1553977-42-6 |
DC44005 |
BTK inhibitor 17
BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research. |
1858206-76-4 |
DC45785 |
Elsubrutinib
Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease. |
1643570-24-4 |
DC46051 |
Zanubrutinib D5
Zanubrutinib D5 (BGB-3111 D5) is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor. |
|
DC46928 |
TL-895
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research. |
1415823-49-2 |
DC47717 |
TAK-020
Featured
TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate. |
1627603-21-7 |
DC47718 |
AS-1763
Featured
AS-1763 is an orally available, potent, and selective BTK inhibitor and shows excellent potency against both wild/C481S mutant BTKs with IC50 of 0.85 nM/0.99 nM. |
2227211-00-7 |
DC47719 |
BTK inhibitor 19
BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM). |
2557174-19-1 |
DC48033 |
BTK-IN-5
BTK-IN-5 is a covalent BTK inhibitor for treating medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes. |
2145152-06-1 |
DC48043 |
BIIB091
Featured
BIIB091 is a novel reversible, selective, potent BTK inhibitor with Kd of 0.07 nM. |
2247614-80-6 |
DC48357 |
BCPyr
BCPyr is a new candidate BTK degrader (DC50 = 800 nM). |
2669844-82-8 |
DC48358 |
BMS-986143
BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases. |
1643372-95-5 |